Capital Investment Advisors LLC Has $382,000 Position in Novo Nordisk A/S (NYSE:NVO)

Capital Investment Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 12.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,435 shares of the company’s stock after buying an additional 478 shares during the quarter. Capital Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $382,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S during the second quarter worth approximately $25,000. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the third quarter worth $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S during the third quarter worth $42,000. Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S during the third quarter worth $48,000. Finally, M&R Capital Management Inc. lifted its stake in Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after purchasing an additional 297 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NVO. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Up 2.2 %

Shares of NVO opened at $82.99 on Thursday. Novo Nordisk A/S has a 52 week low of $80.05 and a 52 week high of $148.15. The stock has a market capitalization of $372.42 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a fifty day moving average of $99.26 and a 200-day moving average of $118.18.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.